GlaxoSmithKline (NYSE:GSK), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.
Motley Fool Returns
Stock Advisor S&P 500
Stock Advisor launched in February of 2002. Returns as of 02/26/2021.Join Stock Advisor
Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return
- 3 Top Dividend Stocks With Yields Over 4%
- GlaxoSmithKline plc (GSK) Q4 2020 Earnings Call Transcript
- Ask A Virologist: How Does GlaxoSmithKline's Potential Coronavirus Vaccine Work?
- EU Regulator Grants Label Expansion for GlaxoSmithKline's Ovarian Cancer Therapy
- GlaxoSmithKline plc (GSK) Q3 2020 Earnings Call Transcript